These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 11860346)
21. The cellular electropharmacology of mexiletine in papillary muscles of guinea pigs chronically treated with amiodarone. Berman ND; Wang LY; Ogilvie RI Can J Cardiol; 1992; 8(1):69-77. PubMed ID: 1617514 [TBL] [Abstract][Full Text] [Related]
23. A comparison of the cellular electrophysiology of mexiletine and sotalol, singly and combined, in canine Purkinje fibers. Berman ND; Loukides JE J Cardiovasc Pharmacol; 1988 Sep; 12(3):286-92. PubMed ID: 2464100 [TBL] [Abstract][Full Text] [Related]
24. Recording of transmembrane action potentials in chronic ischemic heart disease and dilated cardiomyopathy and the effects of the new class III antiarrhythmic agents D-sotalol and dofetilide. Montero M; Schmitt C J Cardiovasc Pharmacol; 1996 Apr; 27(4):571-7. PubMed ID: 8847875 [TBL] [Abstract][Full Text] [Related]
25. Effect of mexiletine, amiodarone and disopyramide on the excitability and refractoriness of canine cardiac fibers: possible relation to antiarrhythmic drug action and classification. Nakaya Y; Elharrar V; Surawicz B Cardiovasc Drugs Ther; 1987 Aug; 1(2):141-53. PubMed ID: 3154317 [TBL] [Abstract][Full Text] [Related]
26. Cellular electrophysiological effect of terikalant in the dog heart. Biliczki P; Acsai K; Virág L; Tálosi L; Jost N; Biliczki A; Papp JG; Varró A Eur J Pharmacol; 2005 Mar; 510(3):161-6. PubMed ID: 15763239 [TBL] [Abstract][Full Text] [Related]
27. Prolongation of the QT interval by dofetilide modulates rate-dependent effects of mexiletine on intraventricular conduction. Todt H; Zojer N; Raberger G; Schütz W Eur J Pharmacol; 1994 Nov; 265(1-2):43-52. PubMed ID: 7883028 [TBL] [Abstract][Full Text] [Related]
28. Class I/B antiarrhythmic property of ranolazine, a novel antianginal agent, in dog and human cardiac preparations. Szél T; Koncz I; Jost N; Baczkó I; Husti Z; Virág L; Bussek A; Wettwer E; Ravens U; Papp JG; Varró A Eur J Pharmacol; 2011 Jul; 662(1-3):31-9. PubMed ID: 21550338 [TBL] [Abstract][Full Text] [Related]
29. Antiarrhythmic effect of a sotalol-mexiletine combination on induced ventricular tachycardia in dogs. Chézalviel F; Weissenburger J; Guhennec C; Jagueux M; Davy JM; Vernhet L; Simandoux V; Poirier JM; Cheymol G J Cardiovasc Pharmacol; 1993 Feb; 21(2):212-20. PubMed ID: 7679154 [TBL] [Abstract][Full Text] [Related]
30. Effects of sematilide, a novel class III antiarrhythmic agent, on action potential in guinea pig atrium. Ishii Y; Muraki K; Kurihara A; Imaizumi Y; Watanabe M Jpn J Pharmacol; 1995 Jun; 68(2):175-82. PubMed ID: 7563974 [TBL] [Abstract][Full Text] [Related]
31. Effects of new and potent methanesulfonanilide class III antiarrhythmic agents on myocardial refractoriness and contractility in isolated cardiac muscle. Baskin EP; Serik CM; Wallace AA; Brookes LM; Selnick HG; Claremon DA; Lynch JJ J Cardiovasc Pharmacol; 1991 Sep; 18(3):406-14. PubMed ID: 1720841 [TBL] [Abstract][Full Text] [Related]
32. Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Varró A; Takács J; Németh M; Hála O; Virág L; Iost N; Baláti B; Agoston M; Vereckei A; Pastor G; Delbruyère M; Gautier P; Nisato D; Papp JG Br J Pharmacol; 2001 Jul; 133(5):625-34. PubMed ID: 11429385 [TBL] [Abstract][Full Text] [Related]
33. Mexiletine-induced shortening of the action potential duration of ventricular muscles by activation of ATP-sensitive K+ channels. Sato T; Shigematsu S; Arita M Br J Pharmacol; 1995 Jun; 115(3):381-2. PubMed ID: 7582444 [TBL] [Abstract][Full Text] [Related]
34. Electrophysiologic interactions between mexiletine-quinidine and mexiletine-ropitoin in guinea pig papillary muscle. Valenzuela C; Sanchez-Chapula J J Cardiovasc Pharmacol; 1989 Nov; 14(5):783-9. PubMed ID: 2481194 [TBL] [Abstract][Full Text] [Related]
35. A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure. Frommeyer G; Milberg P; Witte P; Stypmann J; Koopmann M; Lücke M; Osada N; Breithardt G; Fehr M; Eckardt L Eur J Heart Fail; 2011 Oct; 13(10):1060-9. PubMed ID: 21873342 [TBL] [Abstract][Full Text] [Related]
36. The effect of high extracellular potassium on IKr inhibition by anti-arrhythmic agents. Lin C; Ke X; Cvetanovic I; Ranade V; Somberg J Cardiology; 2007; 108(1):18-27. PubMed ID: 16960444 [TBL] [Abstract][Full Text] [Related]
37. Differential effects of D-sotalol, quinidine, and amiodarone on dispersion of ventricular repolarization in the isolated rabbit heart. Zabel M; Hohnloser SH; Behrens S; Woosley RL; Franz MR J Cardiovasc Electrophysiol; 1997 Nov; 8(11):1239-45. PubMed ID: 9395166 [TBL] [Abstract][Full Text] [Related]
38. Effects of nipradilol (K-351) on the electrophysiological properties of canine cardiac tissues: comparison with propranolol and sotalol. Nakaya H; Kimura S; Nakao Y; Kanno M Eur J Pharmacol; 1984 Sep; 104(3-4):335-44. PubMed ID: 6149947 [TBL] [Abstract][Full Text] [Related]
39. Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle. Jost N; Virág L; Bitay M; Takács J; Lengyel C; Biliczki P; Nagy Z; Bogáts G; Lathrop DA; Papp JG; Varró A Circulation; 2005 Sep; 112(10):1392-9. PubMed ID: 16129791 [TBL] [Abstract][Full Text] [Related]